An evaluation of treatment practices in 13 countries, not including the United States, has shown oral terbinafine to be more cost-effective (from a government payer perspective) than griseofulvin, itraconazole, and ketoconazole in the treatment of onychomycosis of toenails and fingernails.
The purpose of this study was to evaluate the clinical and economic effects of oral griseofulvin, itraconazole, ketoconazole, and terbinafine in the treatment of onychomycosis from the perspective of a third-party payer in the United States.
A previously constructed decision-analytic model evaluating the costs of onychomycosis in 13 countries outside the United States was updated to determine the costs of treating onychomycosis in the United States.
Clinical management patterns were assessed to identify and quantify physician visits, laboratory tests, and adverse drug reaction treatment components for patients with toenail and fingernail onychomycosis.
A random-effects model meta-analysis of treatment efficacy (mycologic cure) and New York Metropolitan Medicare charge data for physician fees were used in the treatment model.
A sensitivity analysis assessing alternative dosing regimens and a rank order stability analysis investigating the effects of length of treatment, success rates, relapse rates, and drug acquisition costs on overall results were also conducted. (...)
Mots-clés Pascal : Antifongique, Voie orale, Etude comparative, Chimiothérapie, Traitement, Mycose, Infection, Ongle, Choix, Coût, Economie santé, Etats Unis, Amérique du Nord, Amérique, Homme, Griséofulvine, Itraconazole, Kétoconazole, Terbinafine
Mots-clés Pascal anglais : Antifungal agent, Oral administration, Comparative study, Chemotherapy, Treatment, Mycosis, Infection, Nail(anatomy), Choice, Costs, Health economy, United States, North America, America, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0441592
Code Inist : 002B02S04. Création : 10/04/1997.